Clinical trials: Myeloma-Multiple

Multiple Myeloma

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

• Active, not recruiting
• Age: 18 years and older
• Phase 3
• Results posted

This open-label, randomized study for evaluating the efficacy and safety of single agent belantamab mafodotin when compared to pom/dex in participants with RRMM.

Trial name

DREAMM-3 (NCT04162210)

Testing

Belantamab mafodotin, Pom/dex (Pomalidomide plus low dose Dexamethasone)

Where

136 sites in United States, Australia and 17 more

Volunteers

325 people

Sponsor

GlaxoSmithKline